Physician profile
Ashok B Raj
NPI 1508840034
$164,818.60
in general payments reported to CMS, 2019-2025
25 companies · $47K in 2025
The $47K reported for 2025 was more than what 96% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,790 · 2020: $8,360 · 2021: $19K · 2022: $22K · 2023: $35K · 2024: $32K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Consulting Fee: $19K · Travel and Lodging: $15K · Food and Beverage: $5,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $73,312.08 |
| Consulting Fee | $19,208.00 |
| Travel and Lodging | $15,226.57 |
| Food and Beverage | $5,635.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $54,590.95 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $49,709.20 | 2021-2025 | |
| Global Blood Therapeutics, INC. | $23,844.50 | 2020-2022 | |
| Genzyme Corporation | $8,922.25 | 2023-2025 | |
| Sobi, INC | $7,560.63 | 2022-2025 | |
| Uswm, LLC | $7,316.34 | 2023-2024 | Iwilfin |
| Genentech USA, INC. | $5,611.76 | 2021-2022 | |
| Terumo Bct, INC. | $2,250.00 | 2020 | |
| Csl Behring | $1,296.64 | 2024 | |
| Merck Sharp & Dohme LLC | $1,245.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $896.36 | 2024 | |
| Hema Biologics, LLC | $400.45 | 2022-2023 | Sevenfact |
| Adaptive Biotechnologies Corporation | $364.07 | 2022-2025 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $246.10 | 2025 | Ultomiris |
| Novo Nordisk INC | $141.64 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $124.74 | 2023 | |
| Amgen INC. | $109.20 | 2021 | |
| Silk Road Medical, INC. | $104.63 | 2021 | |
| Shire North American Group INC | $44.97 | 2019 | |
| Servier Pharmaceuticals LLC | $24.21 | 2024 | |
| Genentech, INC. | $14.78 | 2025 | Hemlibra |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Raj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.